• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国原发性和复发性艰难梭菌感染患者的医疗资源利用和成本归因分析。

Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.

机构信息

Center for Observational and Real-World Evidence, Merck & Co, Inc, Kenilworth, New Jersey.

出版信息

Clin Infect Dis. 2018 Apr 17;66(9):1326-1332. doi: 10.1093/cid/cix1021.

DOI:10.1093/cid/cix1021
PMID:29360950
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5905590/
Abstract

BACKGROUND

The economic burden of Clostridium difficile infection (CDI), the leading cause of nosocomial infectious diarrhea, is not well understood. The objective of this study was to estimate the healthcare resource utilization (HCRU) and costs attributable to primary CDI and recurrent CDI (rCDI).

METHODS

This is a database (MarketScan) study. Patients without CDI were matched 1:1 by propensity score to those with primary CDI but no recurrences to obtain HCRU and costs attributable to primary CDI. Patients with primary CDI but no recurrences were matched 1:1 by propensity score to those with primary CDI plus 1 recurrence in order to obtain HCRU and costs attributable to rCDI. Adjusted estimates for incremental cumulative hospitalized days and healthcare costs over a 6-month follow-up period were obtained by generalized linear models with a Poisson or gamma distribution and a log link. Bootstrapping was used to obtain 95% confidence intervals (CIs).

RESULTS

A total of 55504 eligible CDI patients were identified. Approximately 25% of these CDI patients had rCDI. The cumulative hospitalized days attributable to primary CDI and rCDI over the 6-month follow-up period were 5.20 days (95% CI, 5.01-5.39) and 1.95 days (95% CI, 1.48-2.43), respectively. The healthcare costs attributable to primary CDI and rCDI over the 6-month follow-up period were $24205 (95% CI, $23436-$25013) and $10580 (95% CI, $8849-$12446), respectively.

CONCLUSIONS

The HCRU and costs attributable to primary CDI and rCDI are quite substantial. It is necessary to reduce the burden of CDI, especially rCDI.

摘要

背景

艰难梭菌感染(CDI)是医院获得性传染性腹泻的主要病因,其经济负担尚未得到充分认识。本研究旨在评估原发性 CDI 和复发性 CDI(rCDI)相关的医疗资源利用(HCRU)和成本。

方法

这是一项基于数据库(MarketScan)的研究。通过倾向评分,将无 CDI 的患者与原发性 CDI 但无复发的患者进行 1:1 匹配,以获得原发性 CDI 相关的 HCRU 和成本。将原发性 CDI 但无复发的患者与原发性 CDI 加 1 次复发的患者进行 1:1 匹配,以获得 rCDI 相关的 HCRU 和成本。通过具有泊松或伽马分布和对数链接的广义线性模型,获得 6 个月随访期间累计住院天数和医疗保健费用的调整估计值。使用 bootstrap 方法获得 95%置信区间(CI)。

结果

共确定了 55504 名符合条件的 CDI 患者。这些 CDI 患者中约有 25%患有 rCDI。在 6 个月的随访期间,原发性 CDI 和 rCDI 归因于住院的累计天数分别为 5.20 天(95%CI,5.01-5.39)和 1.95 天(95%CI,1.48-2.43)。在 6 个月的随访期间,原发性 CDI 和 rCDI 归因于医疗保健的费用分别为 24205 美元(95%CI,23436-25013)和 10580 美元(95%CI,8849-12446)。

结论

原发性 CDI 和 rCDI 相关的 HCRU 和成本相当可观。有必要减轻 CDI 的负担,特别是 rCDI。

相似文献

1
Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.美国原发性和复发性艰难梭菌感染患者的医疗资源利用和成本归因分析。
Clin Infect Dis. 2018 Apr 17;66(9):1326-1332. doi: 10.1093/cid/cix1021.
2
Healthcare resource utilization and direct medical costs associated with index and recurrent infection: a real-world data analysis.与首发和复发感染相关的医疗资源利用和直接医疗成本:真实世界数据分析。
J Med Econ. 2020 Jun;23(6):603-609. doi: 10.1080/13696998.2020.1724117. Epub 2020 Feb 13.
3
Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.日本复发性艰难梭菌感染的医疗负担:一项回顾性数据库研究。
J Infect Chemother. 2018 Nov;24(11):892-901. doi: 10.1016/j.jiac.2018.07.020. Epub 2018 Sep 3.
4
Health care resource utilization and costs of recurrent infection in the elderly: a real-world claims analysis.老年人反复感染的医疗资源利用情况及成本:一项真实世界索赔分析。
J Manag Care Spec Pharm. 2021 Jul;27(7):828-838. doi: 10.18553/jmcp.2021.20395. Epub 2021 Mar 11.
5
Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.复发性艰难梭菌感染的影响:住院和患者生活质量。
J Antimicrob Chemother. 2017 Sep 1;72(9):2647-2656. doi: 10.1093/jac/dkx174.
6
Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study.复发性艰难梭菌感染患者的住院再入院预测因素和负担:一项法国全国性的发病队列研究。
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1297-1305. doi: 10.1007/s10096-019-03552-9. Epub 2019 Apr 2.
7
A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.复发性艰难梭菌感染相关成本的综合研究
Infect Control Hosp Epidemiol. 2017 Feb;38(2):196-202. doi: 10.1017/ice.2016.246. Epub 2016 Nov 7.
8
Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.住院患者中初次与复发性艰难梭菌感染的经济负担:一项前瞻性队列研究。
J Hosp Infect. 2016 Jul;93(3):286-9. doi: 10.1016/j.jhin.2016.04.004. Epub 2016 Apr 20.
9
Attributable Cost of Clostridium difficile Infection in Pediatric Patients.艰难梭菌感染患儿的归因成本。
Infect Control Hosp Epidemiol. 2017 Dec;38(12):1472-1477. doi: 10.1017/ice.2017.240. Epub 2017 Nov 27.
10
Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: the RECUR Germany study.估算 2015-2019 年艰难梭菌感染和复发的超额死亡率和经济负担:德国 RECUR 研究。
BMC Infect Dis. 2024 May 31;24(1):548. doi: 10.1186/s12879-024-09422-w.

引用本文的文献

1
Epidemiologic profile of community-acquired infections: a systematic review and meta-analysis.社区获得性感染的流行病学概况:一项系统评价和荟萃分析。
Epidemiol Infect. 2025 Mar 4;153:e46. doi: 10.1017/S0950268825000202.
2
Clinical and economic outcomes associated with fidaxomicin in comparison to vancomycin, metronidazole, and FMT: A systematic literature review.与万古霉素、甲硝唑和粪菌移植相比,非达霉素的临床和经济结果:一项系统文献综述。
Medicine (Baltimore). 2024 Dec 27;103(52):e39219. doi: 10.1097/MD.0000000000039219.
3
Incidence, healthcare and out-of-pocket costs, and mortality of infection among US adults aged 18 to 64 years.

本文引用的文献

1
Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach.美国艰难梭菌的流行病学和经济负担:基于建模方法的估计
BMC Infect Dis. 2016 Jun 18;16:303. doi: 10.1186/s12879-016-1610-3.
2
Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection.兴衰:肠道微生物群对医院暴露和艰难梭菌定植或感染的反应动态。
Microbiome. 2016 Mar 14;4:12. doi: 10.1186/s40168-016-0156-3.
3
Guidelines for good pharmacoepidemiology practice (GPP).
美国18至64岁成年人感染的发病率、医疗保健及自付费用和死亡率。
Antimicrob Steward Healthc Epidemiol. 2024 Dec 11;4(1):e215. doi: 10.1017/ash.2024.400. eCollection 2024.
4
A quantitative PCR to detect non-toxigenic .一种用于检测非产毒型的定量聚合酶链反应。
Microbiol Spectr. 2025 Jan 7;13(1):e0160824. doi: 10.1128/spectrum.01608-24. Epub 2024 Dec 11.
5
Comparison of the STANDARD M10 . , Xpert . , and BD MAX Cdiff assays as confirmatory tests in a two-step algorithm for diagnosing infection.将标准M10、Xpert和BD MAX艰难梭菌检测作为两步诊断算法中感染确认试验的比较。
Microbiol Spectr. 2025 Jan 7;13(1):e0166224. doi: 10.1128/spectrum.01662-24. Epub 2024 Nov 29.
6
Patient Satisfaction Scale Following a Laxative for Antibiotic Washout Prior to Oral Microbiome Therapy.口服微生物组治疗前用于抗生素清除的泻药后的患者满意度量表
Adv Ther. 2025 Jan;42(1):490-499. doi: 10.1007/s12325-024-03065-8. Epub 2024 Nov 28.
7
Costs and Outcomes of Clostridioides difficile Infections in Germany: A Retrospective Health Claims Data Analysis.德国艰难梭菌感染的成本与结局:一项回顾性健康保险索赔数据分析
Infect Dis Ther. 2025 Jan;14(1):91-104. doi: 10.1007/s40121-024-01075-1. Epub 2024 Nov 20.
8
A Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Infection Following the IDSA 2021 Clinical Guideline Update: Infection.对遵循美国感染病学会(IDSA)2021年临床指南更新中感染相关内容的指南依从性和治疗结果的回顾性评估:感染
Open Forum Infect Dis. 2024 Sep 30;11(10):ofae524. doi: 10.1093/ofid/ofae524. eCollection 2024 Oct.
9
Best Practices in the Management of Infection in Developing Nations.发展中国家感染管理的最佳实践
Trop Med Infect Dis. 2024 Aug 19;9(8):185. doi: 10.3390/tropicalmed9080185.
10
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.三叶草(艰难梭菌疫苗疗效试验)研究:一项3期随机试验,调查一种脱毒毒素A/B疫苗在50岁及以上艰难梭菌感染风险增加的成年人中的疗效和安全性。
Clin Infect Dis. 2024 Dec 17;79(6):1503-1511. doi: 10.1093/cid/ciae410.
药物流行病学良好实践指南(GPP)。
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):2-10. doi: 10.1002/pds.3891. Epub 2015 Nov 5.
4
Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.艰难梭菌相关性腹泻的经济负担:来自德国一家三级护理医院的疾病成本研究。
Infection. 2015 Dec;43(6):707-14. doi: 10.1007/s15010-015-0810-x. Epub 2015 Jun 30.
5
Burden of Clostridium difficile infection in the United States.美国艰难梭菌感染的负担
N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913.
6
Attributable inpatient costs of recurrent Clostridium difficile infections.复发性艰难梭菌感染的住院费用归因
Infect Control Hosp Epidemiol. 2014 Nov;35(11):1400-7. doi: 10.1086/678428. Epub 2014 Sep 29.
7
Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update.急性护理医院预防艰难梭菌感染的策略:2014年更新版
Infect Control Hosp Epidemiol. 2014 Jun;35(6):628-45. doi: 10.1086/676023.
8
Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain.艰难梭菌感染的流行病学和不良临床结局的危险因素:西班牙巴塞罗那一项基于医院的研究结果。
J Clin Microbiol. 2013 May;51(5):1465-73. doi: 10.1128/JCM.03352-12. Epub 2013 Feb 27.
9
Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea.高危医院获得性艰难梭菌相关性腹泻患者的住院时间和住院费用。
J Med Econ. 2013;16(3):440-8. doi: 10.3111/13696998.2013.770749. Epub 2013 Feb 6.
10
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.倾向得分法在观察性研究中减少混杂效应的介绍
Multivariate Behav Res. 2011 May;46(3):399-424. doi: 10.1080/00273171.2011.568786. Epub 2011 Jun 8.